Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

United Therapeutics to acquire SteadyMed

Executive Summary

United Therapeutics Corp. is paying $4.46 per share in cash (a 55% premium) to acquire SteadyMed Ltd. United Therapeutics will also shell out $2.63 per share in cash based on a commercialization milestone for Trevyent. The deal is valued at $216mm, which includes $75mm in contingent payments.

Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
      • Transdermal
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register